BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16981845)

  • 1. Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-à-vis the NCI-60 panel.
    Le Morvan V; Bellott R; Moisan F; Mathoulin-Pélissier S; Bonnet J; Robert J
    Pharmacogenomics; 2006 Sep; 7(6):843-52. PubMed ID: 16981845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln polymorphisms are independent prognostic factors for the clinical course of melanoma.
    Schrama D; Scherer D; Schneider M; Zapatka M; Bröcker EB; Schadendorf D; Ugurel S; Kumar R; Becker JC
    J Invest Dermatol; 2011 Jun; 131(6):1280-90. PubMed ID: 21390047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome.
    Le Morvan V; Smith D; Laurand A; Brouste V; Bellott R; Soubeyran I; Mathoulin-Pelissier S; Robert J
    Pharmacogenomics; 2007 Dec; 8(12):1693-703. PubMed ID: 18085999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
    J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleotide excision repair protein levels vis-à-vis anticancer drug resistance in 60 human tumor cell lines.
    Chen ZP; Malapetsa A; Monks A; Myers TG; Mohr G; Sausville EA; Scudiero DA; Panasci LC
    Ai Zheng; 2002 Mar; 21(3):233-9. PubMed ID: 12451985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers?
    Fariña Sarasqueta A; van Lijnschoten G; Lemmens VE; Rutten HJ; van den Brule AJ
    Mol Diagn Ther; 2011 Oct; 15(5):277-83. PubMed ID: 21958378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in XPC, XPD and XPG DNA repair genes and leukemia risk in a Tunisian population.
    Douzi K; Ouerhani S; Menif S; Safra I; Abbes S
    Leuk Lymphoma; 2015 Jun; 56(6):1856-62. PubMed ID: 25311495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An association of selected ERCC2 and ERCC5 genes polymorphisms, the level of oxidative DNA damage and its repair efficiency with a risk of colorectal cancer in Polish population.
    Kabzinski J; Przybylowska K; Dziki L; Dziki A; Majsterek I
    Cancer Biomark; 2015; 15(4):413-23. PubMed ID: 25835182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
    Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
    Monzo M; Moreno I; Navarro A; Ibeas R; Artells R; Gel B; Martinez F; Moreno J; Hernandez R; Navarro-Vigo M
    Oncology; 2007; 72(5-6):364-70. PubMed ID: 18204222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors.
    Yang LM; Li XH; Bao CF
    Asian Pac J Cancer Prev; 2012; 13(11):5883-6. PubMed ID: 23317281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deciphering the role of the ERCC2 gene polymorphism on anticancer drug sensitivity.
    Moisan F; Laroche-Clary A; Auzanneau C; Ricard N; Pourquier P; Robert J; Le Morvan V
    Carcinogenesis; 2012 May; 33(5):962-8. PubMed ID: 22345163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bladder cancer and polymorphisms of DNA repair genes (XRCC1, XRCC3, XPD, XPG, APE1, hOGG1).
    Narter KF; Ergen A; Agaçhan B; Görmüs U; Timirci O; Isbir T
    Anticancer Res; 2009 Apr; 29(4):1389-93. PubMed ID: 19414392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single nucleotide polymorphisms and expression of ERCC1 and ERCC2 vis-à-vis chemotherapy drug cytotoxicity in human glioma.
    Chen H; Shao C; Shi H; Mu Y; Sai K; Chen Z
    J Neurooncol; 2007 May; 82(3):257-62. PubMed ID: 17151930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells.
    Koeppel F; Poindessous V; Lazar V; Raymond E; Sarasin A; Larsen AK
    Clin Cancer Res; 2004 Aug; 10(16):5604-13. PubMed ID: 15328203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
    Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extraneuronal monoamine transporter expression and DNA repair vis-à-vis 2-chloroethyl-3-sarcosinamide-1-nitrosourea cytotoxicity in human tumor cell lines.
    Chen ZP; Remack J; Brent TP; Mohr G; Panasci LC
    Clin Cancer Res; 1999 Dec; 5(12):4186-90. PubMed ID: 10632359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between gene polymorphisms of CYP1A1, GSTP1, ERCC2, XRCC1, and XRCC3 and susceptibility to lung cancer.
    Liu HX; Li J; Ye BG
    Genet Mol Res; 2016 Nov; 15(4):. PubMed ID: 27819744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of tobacco, XPC, ERCC2 and ERCC5 genetic variants in bladder cancer development.
    Rouissi K; Bahria IB; Bougatef K; Marrakchi R; Stambouli N; Hamdi K; Cherif M; Ben Slama MR; Sfaxi M; Othman FB; Chebil M; Elgaaied AB; Ouerhani S
    BMC Cancer; 2011 Mar; 11():101. PubMed ID: 21426550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Polymorphism Lys751Gln of XPD gene and breast cancer risk in women].
    Romanowicz-Makowska H; Smolarz B
    Pol Merkur Lekarski; 2007 Aug; 23(134):107-9. PubMed ID: 18044339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.